Home
Clinical Trials
Study to Evaluate the Safety ...

Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

Last Updated: 2022-02-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

672 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-30

Study Completion Date

2025-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter, randomized, double-blind, parallel, Vildagliptin and Placebo-Controlled study to evaluate the efficacy and safety of oral administration of 100 mg of PB-201 in the morning and evening in treatmentnaive patients with type 2 diabetes mellitus.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Efficacy and Safety of PB-201 in Type 2 Diabetic Mellitus Patients With Poor Glycemic Control Via Metformin Hydrochloride Monotherapy

NCT05326490

Type 2 Diabetes Mellitus

UNKNOWN PHASE3

Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus

NCT03973515

Type2 Diabetes Mellitus

COMPLETED PHASE1

Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects

NCT03520972

Type 2 Diabetes Mellitus

COMPLETED PHASE2

Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome

NCT03081598

Type 2 Diabetes Mellitus Metabolic Syndrome

TERMINATED PHASE2

Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects

NCT04504370

Type 2 Diabetes Mellitus (T2DM)

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study consists of a screening period of up to 2 weeks, a 4-week single-blind run-in period, a 24-week double-blinded treatment period, a 28-week extended treatment period, and a 2-week safety follow-up period.Eligible subjects will be enrolled in a 4-week single-blind run-in period with daily oral administration of 1 tablet of PB-201 matched placebo and 1 Vildagliptin matched placebo in the morning and evening respectively.After the end of the single-blind run-in period, subjects who meet the protocol enrollment requirements will be randomized in the proportion of 2:1:1 to receive double-blinded treatment for 24 weeks in three different treatment groups (test arm, Vildagliptin arm, or placebo arm).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Mellitus (T2DM)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test arm

PB-201: 100 mg each time, orally in the morning and evening respectively; Vildagliptin matched placebo: One tablet each time, orally in the morning and evening respectively;

Group Type EXPERIMENTAL

PB-201

Intervention Type DRUG

PB-201: 100 mg each time, orally in the morning and evening respectively;

Vildagliptin matched placebo

Intervention Type DRUG

One tablet each time, orally in the morning and evening respectively;

Vildagliptin arm

Vildagliptin: 50 mg each time, orally in the morning and evening respectively; PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;

Group Type ACTIVE_COMPARATOR

Vildagliptin

Intervention Type DRUG

Vildagliptin: 50 mg each time, orally in the morning and evening respectively;

PB-201 matched placebo

Intervention Type DRUG

PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;

Placebo arm

PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively; Vildagliptin matched placebo: One tablet each time, orally in the morning and evening respectively;

Group Type PLACEBO_COMPARATOR

PB-201 matched placebo

Intervention Type DRUG

PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;

Vildagliptin matched placebo

Intervention Type DRUG

One tablet each time, orally in the morning and evening respectively;

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PB-201

PB-201: 100 mg each time, orally in the morning and evening respectively;

Intervention Type DRUG

Vildagliptin

Vildagliptin: 50 mg each time, orally in the morning and evening respectively;

Intervention Type DRUG

PB-201 matched placebo

PB-201 matched placebo: One tablet each time, orally in the morning and evening respectively;

Intervention Type DRUG

Vildagliptin matched placebo

One tablet each time, orally in the morning and evening respectively;

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females aged ≥18 years and ≤ 75 years at screening;
* Diagnosed T2DM patients who meet the diagnostic criteria for type 2 diabetes mellitus issued by WHO in 1999 (see Appendix 2 for diagnostic criteria of type 2 diabetes mellitus);
* Receive diet and exercise interventions for at least eight weeks before screening and do not receive any anti-diabetes medications within eight weeks before screening;
* The Glycosylated hemoglobin (HbA1c) must meet the following criteria:

1. HbA1c ≥ 7.5% and ≤ 11.0% at screening (local laboratory);
2. HbA1c ≥ 7.0% and ≤ 10.5% (central laboratory) prior to randomization (V3);
* Body mass index (BMI) ≥ 18.5 kg/m2 and ≤ 40.0 kg/m2 at screening or prior to randomization (V3);
* Able to understand and willing to sign the written informed consent form (ICF) and follow the protocol.

Exclusion Criteria

* Patients cannot be randomized if they meet any of the following criteria:
* Patients diagnosed with type 1 diabetes mellitus, diabetes due to pancreatic injury, or special type of diabetes due to other diseases (e.g., acromegaly or Cushing's syndrome);
* Patients who receive other glucokinase activators prior to screening or randomization;
* Patients who have acute diabetic complications such as diabetic ketoacidosis, lactic acidosis or hyperglycemia and hyperglycemic hyperosmolar status within six months before screening or prior to randomization;
* Patients who have severe chronic diabetic complications (such as proliferative diabetic retinopathy, severe diabetic neuropathy, diabetic foot, etc.) within six months before screening.
* Patients who have two or more episodes of severe hypoglycemia within six months before screening, or who have had severe hypoglycemia prior to randomization since screening ;
* Patients who have hemorrhagic stroke or acute ischemic stroke within six months before screening or prior to randomization;
* Patients who have a history of acute or chronic pancreatitis at screening or prior to randomization;
* Patients who suffer from any serious gastrointestinal diseases (such as gastroparesis, inflammatory bowel disease, intestinal obstruction) that affect drug absorption within six months before screening or prior to randomization, or have underwent gastrointestinal operations that affect drug absorption (such as gastrectomy, gastroenterostomy or enterectomy, etc.);
* Patients who have severe trauma or serious infection that may affect glycaemic control within one month before screening or prior to randomization, such as bone fracture, pneumonia, etc.;
* Patients with any type of treated or untreated malignancy (whether cured or not) within five years before screening or prior to randomization. However, patients with cured basal cell carcinoma of the skin do not need to be excluded;
* Patients with thyroid dysfunction not controlled by stable drug dosage at screening or abnormalities of thyroid function test with clinically significant at screening and requiring medical treatment;
* Patients who have any of the following laboratory abnormalities at screening:

1. Human immunodeficiency virus antibody or Treponema pallidum specific antibody positive;
2. Hepatitis C antibody positive;
3. Hepatitis B surface antigen is positive, and the result of hepatitis B virus DNA quantitative test is higher than the lower limit of the test reference range (Note: If the local laboratory cannot carry out quantitative detection of hepatitis B virus, the sample will be sent to the central laboratory.);
* Patients who have any disease at screening or prior to randomization that may cause hemolysis or red blood cell instability affecting HbA1c testing, such as hemolytic anemia;
* Subject who has participated in any drug or medical device clinical study within three months before screening or prior to randomization (except those who fail in screening or do not receive any trial drug);
* Patients who have a prior history of clearly diagnosed psychiatric disorders, unwilling or unable to fully understand and cooperate, or assessed by the investigator as unsuitable for participation in this clinical study;
* Patients who have a prior history of drinking \[(\>2 units of alcohol per day and \>14 units of alcohol per week (one unit of alcohol corresponds to 150mL of grape wine or 350mL of beer or 50 mL of spirits)\] or history of drug abuse;
* Patients who are known to be allergic or intolerant to the test drug or Vildagliptin or their excipients, or who have contraindications;
* Patients who have refractory urinary or genital infections within six months before screening, or are known to be allergic to Empagliflozin or its excipients;
* Female in pregnancy or lactation period;
* Partners of male subjects or female subjects who plan to become pregnant or who are unable or unwilling to use contraceptive methods required by the protocol from the signing of the informed consent form to 30 days after the last dose of the drug;
* The investigator judges that the subject is unable to comply with the protocol requirements, such as unable to adhere to diet and exercise treatment during the study, unable to take drugs and meals on time according to the protocol requirements, and unable to conduct self-monitoring of blood glucose (SMBG) in time and record;
* Other circumstances that, in the opinion of the investigator, are not appropriate for participation in this clinical study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Linong Ji, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

Peking University People's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.